Literature DB >> 26070519

Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a Cochrane review.

Leopoldo O Tso1, Michael F Costello2, Luiz Eduardo T Albuquerque3, Régis B Andriolo4, Jane Marjoribanks5, Cristiane R Macedo6.   

Abstract

In women with polycystic ovary syndrome, metformin treatment before or during assisted reproductive technology cycles increases clinical pregnancy rates and decreases the risk of ovarian hyperstimulation syndrome. However, there is no conclusive evidence of a benefit in live birth rates.
Copyright © 2015 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Metformin; assisted reproductive techniques; intracytoplasmic sperm injection; in vitro fertilization; polycystic ovary syndrome

Mesh:

Substances:

Year:  2015        PMID: 26070519     DOI: 10.1016/j.fertnstert.2015.05.038

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  4 in total

1.  Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles.

Authors:  M N Kalem; Z Kalem; T Gurgan
Journal:  J Endocrinol Invest       Date:  2017-02-27       Impact factor: 4.256

Review 2.  Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle.

Authors:  Joëlle Dupont; Rex J Scaramuzzi
Journal:  Biochem J       Date:  2016-06-01       Impact factor: 3.857

3.  A healthy HLA-matched baby born by using a combination of aCGH and Karyomapping: the first latin american case.

Authors:  Andrea Delgado; Guillermo Llerena; Rosmary Lopez; Jimmy Portella; Naomi Inoue; Luis Noriega-Hoces; Luis Guzman
Journal:  JBRA Assist Reprod       Date:  2017-12-01

Review 4.  Metformin in Reproductive Biology.

Authors:  Melanie Faure; Michael J Bertoldo; Rita Khoueiry; Alice Bongrani; François Brion; Cecilia Giulivi; Joelle Dupont; Pascal Froment
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-22       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.